One gathers that Mr. Rami Elghandour, President of Arcellx (ACLX +0.09%), has been indulging in a little portfolio adjustment. A mere $10.24 million worth of shares departed his holdings on February 27th, if you please. Perfectly understandable, of course. One does have expenses, and frankly, the market is exhausting. A Form 4 filing confirms the transaction; the paperwork, naturally, is frightful.
A Brief Accounting
| Metric | Value |
|---|---|
| Shares Sold (Direct) | 89,916 |
| Transaction Value | $10.2M |
| Post-Transaction Shares (Direct) | 276,051 |
| Post-Transaction Shares (Indirect) | 416,500 |
| Direct Ownership Value | ~$31.41M |
The weighted average purchase price, as the form so tediously details, was $113.92. Post-transaction, the market closed at $113.79. A negligible difference, naturally, but one must have the numbers, mustn’t one?
The Usual Questions
- Is this unusual behavior? This particular sale, at 89,916 shares, rather eclipses Mr. Elghandour’s typical activity. Since January 2025, his median sale has been a mere 38,300 shares. One suspects a particularly lavish party or, perhaps, a regrettable investment in Impressionist art.
- What does this mean for his stake? Despite the divestment, Mr. Elghandour retains a substantial interest – 276,051 shares directly, and 416,500 through a spousal trust. Enough to maintain a certain… leverage, shall we say.
A Company Snapshot
| Metric | Value |
|---|---|
| Price | $113.79 |
| Market Capitalization | $6.65 billion |
| Net Loss (TTM) | -$228.93 million |
| 1-Year Price Change | 75.55% |
Prices and performance calculated as of February 28th, 2026. One assumes these things are checked, naturally.
The Larger Picture
Arcellx, one gathers, is a biotechnology firm dabbling in immunotherapy. Cancer and other incurable diseases are the targets, naturally. They seem to be catering to a rather demanding clientele – oncology healthcare providers and patients with particularly stubborn ailments. One hopes they’re adequately compensated.
What it All Means
The share price, one observes, has been rather exuberant. However, a rather significant development looms. On February 23rd, 2026, the company announced it will be acquired by Gilead Sciences (GILD +0.45%). A perfectly respectable firm, naturally. The estimated value is $7.8 billion – $115 per share, plus a contingent value right of $5. A tidy sum, all told.
They’ve also had a breakthrough with their multiple myeloma treatment, advancing it to Phase 2 development. And a blood cancer immunotherapy is awaiting FDA approval, with a decision expected by December 2026. If successful, it could be a rather lucrative product. However, with the merger pending, one wonders how long investors can continue to trade shares. A rather inconvenient truth, naturally.
Read More
- Gold Rate Forecast
- Top 15 Insanely Popular Android Games
- EUR UAH PREDICTION
- 4 Reasons to Buy Interactive Brokers Stock Like There’s No Tomorrow
- Did Alan Cumming Reveal Comic-Accurate Costume for AVENGERS: DOOMSDAY?
- Silver Rate Forecast
- DOT PREDICTION. DOT cryptocurrency
- ELESTRALS AWAKENED Blends Mythology and POKÉMON (Exclusive Look)
- Core Scientific’s Merger Meltdown: A Gogolian Tale
- New ‘Donkey Kong’ Movie Reportedly in the Works with Possible Release Date
2026-03-02 18:14